Status:
RECRUITING
Risk Assessment for HBV-Related Liver Cancer
Lead Sponsor:
Sun Yat-sen University
Conditions:
HBV-related Liver Cirrhosis
Eligibility:
All Genders
30-75 years
Brief Summary
Liver cancer is a severe disease worldwide. The incidence and mortality rates of liver cancer in China is the highest in the world. This project aims to perform a prospective, multi-center, large samp...
Eligibility Criteria
Inclusion
- must meet (a) and any one of (b) to (g).
- (a).Positive for Hepatitis B surface antigen; (b).Ultrasound/CT/MR indicates liver cirrhosis; (c). Type II diabetes; (d). Has family history of liver cirrhosis/ liver cancer; (e). Long term alcohol consumption history (\>5 years), equivalent to alcohol consumption of ≥ 40g/d for males and ≥ 20g/d for females; (f). Liver histology Metavir fibrosis score F3 or above; (g). Fibroscan value (LSM) ≥ 8.0kPa.
Exclusion
- (a).Diagnosed with malignant tumors; (b). Post liver transplantation; (c). Infected with HIV; (d). Expected survival time\<1 year; (e). With marked organ dysfunctions(heart, brain, kidney, lung, endocrine system, blood, etc.) or psychiatric patients.
Key Trial Info
Start Date :
May 10 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2032
Estimated Enrollment :
6000 Patients enrolled
Trial Details
Trial ID
NCT07160946
Start Date
May 10 2025
End Date
December 30 2032
Last Update
September 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510630